Levodopa and Pramipexole induce different striatal expression profiles in an animal model of parkinsonism

CELIA LARRAMENDY; GERMÁN GONZÁLEZ; FLOOR SPAANS; MARIANO DIEGO SABORIDO; IRENE TARAVINI; ELMER FERNÁNDEZ; MARIO MURER; OSCAR GERSHANIK

Buenos Aires

Congreso; 14th International Congress on Parkinson’s Disease and Movement Disorders; 2010

Movement Disorder Society

Both L-dopa and PRA are widely used Parkinson´s disease (PD) clinics. Initially L-dopa works sufficiently against the symptoms of PD; however, when taken for long periods of time, L-dopa has been known to induce dyskinesias. Lower risks of dyskinesias are observed when D2 dopamine receptor agonists, like PRA, are used. Although there have been several studies published on the gene expression profile induced by the nigrostriatal dennervation and by L-dopa therapy in patients, and in animal models, only a few have dealt with the gene expression profile induced by dopamine agonists.